Novel prodrugs for selective anticancer therapy

Novel prodrugs for selective anticancer therapy

BACKGROUND 

Anticancer drug sales exceeded $50 billion worldwide in 2009 with impressive growth; however, lack of target selectivity is a major challenge in cancer treatment. The limitation of current chemotherapy is in delivering high enough concentrations of cytotoxic drug to the target site in order to completely eradicate the tumor without harming healthy cells. Therefore, a technology that can enhance target selectivity would significantly improve clinical outcomes as well as quality of life for patients and thus have the potential to create novel drugs that can take over and dominate the market.

DESCRIPTION 
Dr. Nobuhide Ueki and Dr. Michael Hayman at Stony Brook University have developed novel methods and compositions to make anticancer prodrugs by conjugating unique dual-substrate biochemical modules to known or novel chemotherapeutic drugs. The requirement of sequential activation by two independent key enzymes acting in tumor cells makes the prodrugs highly selective, resulting in fewer side effects compared to existing anticancer drugs in clinical use. In addition, these novel prodrugs have been shown to be much more stable and resistant to non-specific activation by ubiquitous proteases in cytoplasm or plasma than existing prodrugs.
ADVANTAGES 

Better selectivity with minimal adverse effects l Reduced nonspecific activation by ubiquitous proteases in cytoplasm or plasma l Ability to "repackage" existing generic chemotherapeutic drugs to improve selectivity

APPLICATION 

Anticancer drug therapy l Prodrug formulation

ADDITIONAL INFORMATION 

Further reading: Ueki et al., 4:2735, 2013

DEVELOPMENT STAGE 
Proof of concept data is available.
PATENT STATUS 

US Utility pending (#14/428,501)

ADDITIONAL INFORMATION

INVENTORS 

Michael Hayman
Professor

Nobuhide Ueki
Research Scientist

CASE MANAGER 
Anupam Jhingran
LICENSING STATUS 

Available for License

LICENSING POTENTIAL 
We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.
TECHNOLOGY ID 
8378
PRIMARY KEY 
352828
KEYWORDS 

Anticancer drug therapy l Chemotherapeutic prodrugs l Cancer

Go to top